• 제목/요약/키워드: gastrointestinal motility dysfunction

검색결과 14건 처리시간 0.021초

기능성 위장관 질환에서 핵의학 검사의 역할 (Scintigraphic Evaluation of Gastrointestinal Motility Disorders)

  • 최재걸
    • 대한핵의학회지
    • /
    • 제35권1호
    • /
    • pp.1-11
    • /
    • 2001
  • Current scintigraphic tests of gastrointestinal motor function provides relevant pathophysiologic information, but their clinical utility is controversial. Many scintigraphic methods are developed to investigate gastrointestinal motility from oral cavity to colon. These are esophageal transit scintigraphy, oropharyngeal transit study, gastric emptying test, small bowel transit time measurement, colon transit study and gastroesopahgeal reflux scintigraphy. Scintigraphy of gastrointestinal tract is the most physiologic and noninvasive method to evaluate gastrointestinal motility disorders. Stomach emptying test is regarded as a gold standard in motility study. Gastrointestinal transit scintigraphy also has a certain role in assessment of drug effect to GI motility and changes alter therapy of motility disorders. Scintigraphy provides noninvasive and quantitative assessment of physiological transit throughout the gastrointestinal tract, and it is extremely useful for diagnosing gastrointestinal motor dysfunction. This article reviews the current procedures, indications, significance and guidelines for gastrointestinal motility measurements by scintigraphy.

  • PDF

Clinical Applications of Gastrointestinal Manometry in Children

  • Hong, Jeana
    • Pediatric Gastroenterology, Hepatology & Nutrition
    • /
    • 제17권1호
    • /
    • pp.23-30
    • /
    • 2014
  • Manometry is a noninvasive diagnostic tool for identifying motility dysfunction of the gastrointestinal tract. Despite the great technical advances in monitoring motility, performance of the study in pediatric patients has several limitations that should be considered during the procedure and interpretation of the test results. This article reviews the clinical applications of conventional esophageal and anorectal manometries in children by describing a technique for performing the test. This review will develop the uniformity required for the methods of performance, the parameters for measurement, and interpretation of test results that could be applied in pediatric clinical practice.

Synergic Effect of Trimebutine Combined with Mosapride on Gastrointestinal Dysfunction and Visceral Pain Induced in Stress Models

  • Park, Young-Joon;Park, Yong-Sul;Chung, Zoo-Chul;Nam, Yun-Sung;Chung, Yoon-Hee;Cho, Kwan-Hyung;Choi, Sung-Up;Sohn, Uy-Dong;Park, Eon-Sub;Je, Hyun-Dong;Lee, Choong-Ho;Lee, Moo-Yeol;Jeong, Ji-Hoon
    • Biomolecules & Therapeutics
    • /
    • 제19권1호
    • /
    • pp.84-89
    • /
    • 2011
  • The present study was undertaken to determine whether combined treatment with prokinetic trimebutine and mosapride has a synergic effect on gastrointestinal motility and visceral pain associated with gastrointestinal dysfunction. To develop effective gastroprokinetic agents with greater potencies than trimebutine or mosapride for the treatment of gastrointestinal tract disease, a mixture of trimebutine and mosapride was designed and prepared. In the present study, treatment with trimebutine alone showed a dose-dependent effect on propelling movements of normal small and large intestine in mice, whereas mosapride effected only small intestine motility. Co-administration of trimebutine with mosapride, a well-established prokinetic drug, produced a synergistic influence on normal small intestine motility, but demonstrated an unclear effect on large intestine motility, with a slight tendency to reduce the propelling time. In a stress model, the small and large intestine motilities were significantly decreased. The reduction of intestine motility was restored to a normal level and the restoring effect was more pronounced in the combined treatment with trimebutine plus mosapride than treatment with trimebutine or mosapride alone. Furthermore, treatment with trimebutine plus mosapride significantly decreased acute visceral pain which was not controlled by trimebutine or mosapride alone. These data suggest that combination therapy with trimebutine plus mosapride has a synergic effect on small and large intestine motility and visceral pain control in gastrointestinal disorders.

소청룡탕 추출물의 당뇨병 질환에서 위장관 운동 기능 개선에 관한 연구 (Effects of Socheongryong-Tang, a Traditional Chinese Medicine, on Gastrointestinal Motility Disorders (Diabetic Models) in Mice)

  • 배진수;김익성;서병도;김병주
    • 한방비만학회지
    • /
    • 제17권2호
    • /
    • pp.61-67
    • /
    • 2017
  • Objectives: The purpose of this study was to investigate the effects of Socheongryong-tang, a traditional herbal medicine, on gastrointestinal (GI) motility disorders (inflammatory and diabetic models) in mice. Methods: The in vivo effects of Socheongryong-tang on GI motility were investigated by calculating percent intestinal transit rates (ITR) and gastric emptying (GE) values using Evans Blue and phenol red, respectively, in normal mice and in mice with experimentally induced GI motility dysfunction (GMD). GMD models were induced by acetic acid and streptozotocin. Results: In normal ICR mice, ITR and GE values were significantly and dose-dependently increased by the intragastric administration of Socheongryong-tang (0.0025~0.25 g/kg). The ITR values (%) of GMD mice were significantly lower than those of normal mice, and these reductions were significantly and dose-dependently inhibited by Socheongryong-tang. Conclusions: These results suggest that Socheongryong-tang is a good candidate for the development of a prokinetic agent that may prevent or alleviate GMD.

생맥산 및 평위산 추출물의 위장관 운동 조절 효능에 관한 연구 (Effects of Traditional Chinese Herbal Medicine Shengmai-San and Pyungwi-San on Gastrointestinal Motility in Mice)

  • 이민철;박진령;심지환;안태석;김병주
    • 한방비만학회지
    • /
    • 제15권2호
    • /
    • pp.68-74
    • /
    • 2015
  • Objectives: The purpose of this study was to investigate the effects of Shengmai-san and Pyungwi-san, a herbal product used in traditional Chinese medicine, on gastrointestinal (GI) motility in mice. Methods: The in vivo effects of Shengmai-san and Pyungwi-san on GI motility were investigated by measuring the intestinal transit rates (ITRs) using Evans blue in normal mice and in mice with experimentally induced GI motility dysfunction (GMD). GMD was induced by injecting acetic acid or streptozotocin intraperitoneally. Results: In normal Institute of Cancer Research mice, ITRs were significantly and dose-dependently increased by Shengmaisan (0.01~1 g/kg) and Pyungwi-san (0.01~1 g/kg). The ITRs of acetic acid induced peritoneal irritation model and streptozotocin-induced diabetic model mice were significantly reduced compared to normal mice, and these reductions were significantly and dose-dependently inhibited by Shengmai-san (0.01~1 g/kg) and Pyungwi-san (0.01~1 g/kg). Conclusions: These results suggest that both Shengmai-san and Pyungwi-san are a good candidate for the development of a prokinetic agent that may prevent or alleviate GMD.

Effect of Baekyeum on Intestinal Motility

  • Lim Jong Won;Cho Jung Hyo;Son Chang Gue;Shin Jang Woo;Lee Yeon Weol;Yoo Hwa Seung;Lee Nam Hun;Yun Dam Hee;Cho Chong Kwan
    • 대한한의학회지
    • /
    • 제26권4호
    • /
    • pp.56-61
    • /
    • 2005
  • Objectives: The purpose of this study was to evaluate the effects of Baekyeum (BKE) on intestinal motility. Methods: The effects of BKE on intestinal motility at the physiological state were evaluated by determination of intestinal motility after administration of a charcoal meal. The effects of BKE on intestinal motility at cabachol-induced activated state and loperamide induced suppressed state were also evaluated by determination of intestinal motility after administration of charcoal meal. Results: BKE didn't affect the intestinal motility in physiological state, and BKE didn't affect the intestinal motility at the carbachol-induced activated state. BKE activated significantly the intestinal motility at the loperamide-induced suppressed state. Conclusions: It can be concluded that BKE is an effective herbal prescription for cancer-patients with gastrointestinal dysfunction, especially intestinal stasis.

  • PDF

만성 위장장애를 호소하는 히스테리성 성격의 여자 (A Case of Woman with Histrionic Personality who Suffered from Chronic Gastrointestinal Dysfunction)

  • 송지영
    • 정신신체의학
    • /
    • 제1권1호
    • /
    • pp.101-108
    • /
    • 1993
  • A case of a 38 year-old woman with histrionic personality who had chronic epigastric pain, dyspepsia and alternating bowel habit for more than 10 years was presented in detail on its course of two times of admission and follow-up. The diagnosis was thought as psychophy-siological disorder or gastrointestinal motility disorder of undefined etiology rather than hypo-chondriasis or Briquet's syndrome. She was characterized by sustained illness behavior and combined several physical illnesses. i.e. tuberculosis. anemia and hepatic stone. These physical diseases led to a blurring of psychological and physical boundaries regarding symptom formation. The points on consultation from medical part to psychiatric department were discussed and the supposed causal mechanisms in non-organic functional gastrointestinal disturbances were also reviewed. Physical and psychological modalities for the treatment and the abnormal illness behavior were mainly emphasized in this case.

  • PDF

용담 열수 추출물이 위장관 운동 기능 저해 상황에서 위장관 이송률에 미치는 영향 (Effects of Dried Gentiana scabra Rhizomes and Roots on the Intestinal Transit Rate of Mice with Experimental Gastrointestinal Motility Dysfunctions)

  • 이현태
    • 생명과학회지
    • /
    • 제29권12호
    • /
    • pp.1345-1350
    • /
    • 2019
  • 한약재로 쓰이는 용담(Gentiana scabra)의 열수 추출물(GS-W)을 정상 마우스에 경구 투여할 경우 in vivo 위장관이송률(ITR)이 유의적이고 용량 의존적으로 증가한다는 사실이, 최근 본 연구진에 의해 보고된 바 있다. 이에 본 연구에서는, in vivo 실험적 위장관 운동 기능 저해(GMD) 마우스 모델에서는 GS-W가 ITR에 어떠한 영향을 미치는지 검정하고자 하였다. GS-W는 5 g/kg의 고용량 경구 투여 시에도 정상 마우스에서 급성 독성을 나타내지 않았고, GMD 마우스에서 ITR을 유의적이고 용량 의존적으로 증가시켰으며, 특히 1 g/kg 경구 투여 시의 ITR은 cisapride 투여 시보다 수치 상으로 높았다. 이러한 결과들은, 1990년대까지 임상적으로 널리 처방되었으나 치명적인 부작용으로 인해 2000년 이후 시장에서 철수된 약물인 cisapride를 GS-W가 대체하여, 인간의 다양한 GMD 상황을 예방하거나 그 증상을 완화시킬 수 있는 잠재력이 있음을 시사한다.

위장관장애에 영향을 미치는 심리적 요인 (Psychological Factors Affecting Gastrointestinal Disorders : Functional GI Disorders)

  • 송지영
    • 정신신체의학
    • /
    • 제6권2호
    • /
    • pp.210-220
    • /
    • 1998
  • The relationships between emotion, stress and gastro-intestinal dysfunction were briefly reviewed. Until now, several kinds of theories on about pathophysiology, such as motility dysfunction, changes of pain perception on the lumen, dysregulations on the central nervous system associated with psychosocial factors were reported. However, none of those factors could'nt give any clues for the causes of the functional bowel disorders. For understanding the meaning of the symptoms and for the treatment approach, clinicians should give attention to the comprehensive point of view, i.e., not only biological but also psychological aspects of the patients with non-organic bowel dysfunctions. Giving warm and kind explanations to the patient about symptom formation and progression and understanding the patient's illness behaviors, and good and strong doctor-patient relationship is essentials for the treatment.

  • PDF

시스플라틴으로 유발된 랫트의 위장관 운동장애에 대한 태음조위탕의 효과 (Beneficial Effect of Taeumjowi-tang on the Cisplatin-Induced Gastrointestinal Dysfunctions in Rats)

  • 김성태;최애련
    • 사상체질의학회지
    • /
    • 제27권2호
    • /
    • pp.254-269
    • /
    • 2015
  • Objectives This study aimed to observe the effect of Taeumjowi-tang on the cisplatin-induced gastrointestinal dysfunctions in rats. Methods Four groups, each of 8 rats per group, were used in this study. Saline and distilled water treated control rats were intact vehicle control group. Delayed gastrointestinal motility was induced by intraperitoneal treatment of cisplatin 2mg/kg, once a week for 5 weeks(Cisplatin control group). Taeumjowi-tang aqueous extracts(TJ) were orally administered in a volume of 5ml/kg, once a day for 14 days from 4th cisplatin treatment(TJ group). Ondansetron 1mg/kg was subcutaneously treated, in a volume of 1ml/kg, as same as TJ(ondansetron group). We measured the body weights, intestinal charcoal transit ratio, fecal parameters, fundus MDA(malondialdehyde), GSH(glutathione) contents and SOD(superoxide dismutase), CAT(catalase) activities, TPH(tryptophanhydroxylase) and MAO(monoamine oxidase) activities, pyloric gastrin and serotonin contents with their immunoreactive cells, colonic serotonin-immunoreactive cells, the histopathology of pylorus, fundus mucosa and colon. Results 1) The body weight gains, the small intestinal charcoal transfer rates, the fecal parameters(numbers, weights and water contents) were increased in TJ, ondansetron group. 2) The inhibit of fundus antioxidant defense systems by cisplatin were decreased in TJ, ondansetron group. 3) The pyloric TPH activities were increased and the pyloric MAO activities were decreased in TJ group. 4) The pyloric gastric contents and the gastrin-immunoreactive cells were increased and the pyloric serotonin contents and the pyloric and colonic serotonin-immunoreactive cells were decreased in TJ group. 5) The pylorus atrophic changes and the gastric surface erosive damage regions by cisplatin were favorably inhibited by treatment of TJ group. Conclusions The results obtained in this study suggest that TJ favorably retarded the cisplatin related GI(gastrointestinal) dysfunctions and constipation through modulations of GI enterochromaffin cells, serotonin and gastrin-producing cells and antioxidative systems.